Refashioning dexpramipexole: A new horizon in eosinophilic asthma?

Affiliations

¹ Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland.
² Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Cave Hill, Barbados.
³ Faculty of Health Sciences, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: gauvreau@mcmaster.ca.

Editorial

Ruth P Cusack et al. J Allergy Clin Immunol. 2023 Nov.

. 2023 Nov;152(5):1092-1094.

doi: 10.1016/j.jaci.2023.09.019. Epub 2023 Sep 26.

¹ Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland.
² Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Cave Hill, Barbados.
³ Faculty of Health Sciences, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: gauvreau@mcmaster.ca.

No abstract available

Keywords: Eosinophilic asthma; clinical trial; dexpramipexole; eosinophils.

Comment on

Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): A randomized controlled trial.
Siddiqui S, Wenzel SE, Bozik ME, Archibald DG, Dworetzky SI, Mather JL, Killingsworth R, Ghearing N, Schwartz JT, Ochkur SI, Jacobsen EA, Busse WW, Panettieri RA, Prussin C. Siddiqui S, et al. J Allergy Clin Immunol. 2023 Nov;152(5):1121-1130.e10. doi: 10.1016/j.jaci.2023.05.014. Epub 2023 Jun 3. J Allergy Clin Immunol. 2023. PMID: 37277072 Clinical Trial.